Flavonoids in neurodegeneration: Limitations and strategies to cross CNS barriers

Current Medicinal Chemistry

Volumn 23, Issue 36, 2016, Pages 4151-4174

  Andrade, Paula Branquinho ^a   Grosso, Clara ^a   Valentao, Patricia ^a   Bernardo, Joao ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Blood brain barrier; Brain delivery; Flavonoids; Nano carriers; Neurodegeneration; Permeability; Transporters

Indexed keywords

BETA GLUCURONIDASE; BREAST CANCER RESISTANCE PROTEIN; CATECHIN; EPICATECHIN; FLAVONOID; MULTIDRUG RESISTANCE PROTEIN; ABC TRANSPORTER; ANTHOCYANIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN;

ACTIVE TRANSPORT; ANTIINFLAMMATORY ACTIVITY; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TRACT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; NERVE DEGENERATION; NONHUMAN; PREDICTION; REVIEW; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS; METABOLISM; NEURODEGENERATIVE DISEASES;

ANIMALS; ANTHOCYANINS; ATP-BINDING CASSETTE TRANSPORTERS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CREB-BINDING PROTEIN; FLAVONOIDS; HUMANS; NEURODEGENERATIVE DISEASES; P-GLYCOPROTEIN;

EID: 85006699128     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160809094934     Document Type: Review

References (197)

1. Olesen, J.; Gustavsson, A.; Svensson, M.; Wittchen, H.U.; Jonsson, B. CDBE2010 study group; European Brain Council. The economic cost of brain disorders in Europe. Eur. J. Neurol., 2012, 19(1), 155-162.
2. Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol., 2011, 7(3), 137-152.
3. de Lau, L.M.; Breteler, M.M. Epidemiology of Parkinson's disease. Lancet Neurol., 2006, 5(6), 525-535.
4. Ferrari, A.J.; Somerville, A.J.; Baxter, A.J.; Norman, R.; Patten, S.B.; Vos, T.; Whiteford, H.A. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol. Med., 2013, 43(3), 471-481.
5. Gomes, N.G.; Campos, M.G.; Orfao, J.M.; Ribeiro, C.A. Plants with neurobiological activity as potential targets for drug discovery. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(8), 1372-1389.
6. Kumar, V. Potential medicinal plants for CNS disorders: an overview. Phytother. Res., 2006, 20(12), 1023-1035.
7. Vauzour, D. Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid. Med. Cell. Longev., 2012, 2012, 914273.
8. Ebrahimi, A.; Schluesener, H. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Ageing Res. Rev., 2012, 11(2), 329-345.
9. Bhullar, K. S.; Rupasinghe, H. P. V. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid. Med. Cell. Longev., 2013, 2013, 891748.
10. Gomez-Pinilla, F.; Nguyen, T.T. Natural mood foods: the actions of polyphenols against psychiatric and cognitive disorders. Nutr. Neurosci., 2012, 15(3), 127-133.
11. Pereira, D.M.; Valentao, P.; Pereira, J.; Andrade, P.B. Phenolics: from chemistry to biology. Molecules, 2009, 14(6), 2202-2211.
12. Bravo, L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev., 1998, 56(11), 317-333.
13. Lambert, J.D.; Sang, S.; Yang, C.S. Possible controversy over dietary polyphenols: benefits vs risks. Chem. Res. Toxicol., 2007, 20(4), 583-585.
14. Kumar, Shashank; Pandey, Abhay K. Chemistry and biological activities of flavonoids: an overview. Hindawi Publ. Corp., 2013, 2013, 1-16.
15. Xiao, Z.P.; Peng, Z.Y.; Peng, M.J.; Yan, W.B.; Ouyang, Y.Z.; Zhu, H.L. Flavonoids health benefits and their molecular mechanism. Mini Rev. Med. Chem., 2011, 11(2), 169-177.
16. Jager, A.K.; Saaby, L. Flavonoids and the CNS. Molecules, 2011, 16(2), 1471-1485.
17. Heim, K.E.; Tagliaferro, A.R.; Bobilya, D.J. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J. Nutr. Biochem., 2002, 13(10), 572-584.
18. Rendeiro, C.; Rhodes, J.S.; Spencer, J.P. The mechanisms of action of flavonoids in the brain: Direct versus indirect effects. Neurochem. Int., 2015, 89, 126-139.
19. Yi, L.T.; Xu, H.L.; Feng, J.; Zhan, X.; Zhou, L.P.; Cui, C.C. Involvement of monoaminergic systems in the antidepressant- like effect of nobiletin. Physiol. Behav., 2011, 102(1), 1-6.
20. Wang, W.; Wang, F.; Yang, Y. J.; Hu, Z. L.; Long, L. H.; Fu, H. Wang, W.; Wang, F.; Yang, Y.J.; Hu, Z.L.; Long, L.H.; Fu, H.; Xie, N.; Chen, J.G. The flavonoid baicalein promotes NMDA receptor-dependent long-term potentiation and enhances memory. Br. J. Pharmacol., 2011, 162(6), 1364-1379.
21. Nakajima, A.; Yamakuni, T.; Matsuzaki, K.; Nakata, N.; Onozuka, H.; Yokosuka, A.; Sashida, Y.; Mimaki, Y.; Ohizumi, Y. Nobiletin, a citrus flavonoid, reverses learning impairment associated with N-methyl-D-aspartate receptor antagonism by activation of extracellular signal-regulated kinase signaling. J. Pharmacol. Exp. Ther., 2007, 321(2), 784-790.
22. Meireles, M.; Moura, E.; Vieira-Coelho, M.A.; Santos- Buelga, C.; Gonzalez-Manzano, S.; Duenas, M.; Mateus, N.; Faria, A.; Calhau, C. Flavonoids as dopaminergic neuromodulators. Mol. Nutr. Food Res., 2016, 60(3), 495-501.
23. Hanrahan, J.R.; Chebib, M.; Johnston, G.A. Flavonoid modulation of GABA(A) receptors. Br. J. Pharmacol., 2011, 163(2), 234-245.
24. Ren, L.; Wang, F.; Xu, Z.; Chan, W.M.; Zhao, C.; Xue, H. GABA(A) receptor subtype selectivity underlying anx iolytic effect of 6-hydroxyflavone. Biochem. Pharmacol., 2010, 79(9), 1337-1344.
25. Vina, D.; Serra, S.; Lamela, M.; Delogu, G. Herbal natural products as a source of monoamine oxidase inhibitors: a review. Curr. Top. Med. Chem., 2012, 12(20), 2131-2144.
26. Orhan, I.E. Potential of natural products of herbal origin as monoamine oxidase inhibitors. Curr. Pharm. Des., 2016, 22(3), 268-276.
27. Uriarte-Pueyo, I.; Calvo, M.I. Flavonoids as acetylcholinesterase inhibitors. Curr. Med. Chem., 2011, 18(34), 5289-5302.
28. Katalinić, M.; Rusak, G.; Domaćinović Barović, J.; Šinko, G.; Jelić, D.; Antolović, R.; Kovarik, Z. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur. J. Med. Chem., 2010, 45(1), 186-192.
29. Zhu, X.; Jia, Y.-H. Inhibition of catechol-o-methyltransferase (COMT) by myricetin, dihydromyricetin, and myricitrin. Pharmazie, 2014, 69(3), 183-186.
30. Shimmyo, Y.; Kihara, T.; Akaike, A.; Niidome, T.; Sugimoto, H. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim. Biophys. Acta, 2008, 1780(5), 819-825.
31. Jones, Q.R.; Warford, J.; Rupasinghe, H.P.; Robertson, G.S. Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol. Sci., 2012, 33(11), 602-610.
32. Spencer, J.P.; Vafeiadou, K.; Williams, R.J.; Vauzour, D. Neuroinflammation: modulation by flavonoids and mechanisms of action. Mol. Aspects Med., 2012, 33(1), 83-97.
33. Vauzour, D.; Vafeiadou, K.; Rodriguez-Mateos, A.; Rendeiro, C.; Spencer, J.P. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr., 2008, 3(3- 4), 115-126.
34. Spencer, J. P. E. Flavonoids: modulators of brain function? Br. J. Nutr., 2008, 99(E Suppl (E-S1)), ES60-ES77.
35. Gong, J.; Huang, J.; Ge, Q.; Chen, F.; Zhang, Y. Advanced research on the antidepressant effect of flavonoids. Curr. Opin. Complement. Altern. Med, 2014, 1(2), e00011.
36. Scapagnini, G.; Davinelli, S.; Drago, F.; De Lorenzo, A.; Oriani, G. Antioxidants as antidepressants: fact or fiction? CNS Drugs, 2012, 26(6), 477-490.
37. Trebaticka, J. Dùraćkova, Z. Psychiatric disorders and polyphenols: can they be helpful in therapy? Oxid. Med. Cell. Longev., 2015.
38. Grosso, C.; Valentao, P.; Ferreres, F.; Andrade, P.B. The use of flavonoids in central nervous system disorders. Curr. Med. Chem., 2013, 20(37), 4694-4719.
39. Baptista, F.I.; Henriques, A.G.; Silva, A.M.; Wiltfang, J.; da Cruz e Silva, O.A.; Silva, O.B. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS Chem. Neurosci., 2014, 5(2), 83-92.
40. Williams, R.J.; Spencer, J.P. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic. Biol. Med., 2012, 52(1), 35-45.
41. Magalingam, K.B.; Radhakrishnan, A.K.; Haleagrahara, N. Protective mechanisms of flavonoids in Parkinson's disease. Oxid. Med. Cell. Longev., 2015, 2015, 314560.
42. Solanki, I.; Parihar, P.; Mansuri, M.L.; Parihar, M.S. Flavonoid- based therapies in the early management of neurodegenerative diseases. Adv. Nutr., 2015, 6(1), 64-72.
43. Thilakarathna, S.H.; Rupasinghe, H.P. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients, 2013, 5(9), 3367-3387.
44. Walle, T.; Browning, A.M.; Steed, L.L.; Reed, S.G.; Walle, U.K. Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans. J. Nutr., 2005, 135(1), 48-52.
45. Day, A. J.; Canada, F. J.; Diaz, J. C.; Kroon, P.; McLauchlan, R.; Faulds, C. B.; Plumb, G. W.; Morgan, M. R. A.; Williamson, G. Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans. J. Nutr., 2005, 135(1), 48-52.
46. Nemeth, K.; Plumb, G.W.; Berrin, J-G.; Juge, N.; Jacob, R.; Naim, H.Y.; Williamson, G.; Swallow, D.M.; Kroon, P.A. Deglycosylation by small intestinal epithelial cell β - glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr., 2003, 42(1), 29-42.
47. Walle, T. Absorption and metabolism of flavonoids. Free Radic. Biol. Med., 2004, 36(7), 829-837.
48. Jiang, W.; Hu, M. Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways. RSC Advances, 2012, 2(21), 7948-7963.
49. Aura, A.M. Microbial metabolism of dietary phenolic compounds in the colon. Phytochem. Rev., 2008, 7(3), 407-429.
50. Sousa, C.; Andrade, P.B. V alentao, P. Relationships of Echium plantagineum L. bee pollen, dietary flavonoids and their colonic metabolites with cytochrome P450 enzymes and oxidative stress. RSC Adv., 2016, 6(8), 6084-6092.
51. Chen, J.; Wang, S.; Jia, X.; Bajimaya, S.; Lin, H.; Tam, V.H.; Hu, M. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab. Dispos., 2005, 33(12), 1777-1784.
52. Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37(1), 13-25.
53. Abbott, N.J.; Ronnback, L.; Hansson, E. Astrocyteendothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7(1), 41-53.
54. Cardoso, F.L.; Brites, D.; Brito, M.A. Looking at the bloodbrain barrier: molecular anatomy and possible investigation approaches. Brain Res. Brain Res. Rev., 2010, 64(2), 328-363.
55. Begley, D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther., 2004, 104(1), 29-45.
56. Shawahna, R.; Uchida, Y.; Decleves, X.; Ohtsuki, S.; Yousif, S.; Dauchy, S.; Jacob, A.; Chassoux, F.; Daumas- Duport, C.; Couraud, P.O.; Terasaki, T.; Scherrmann, J.M. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm., 2011, 8(4), 1332-1341.
57. Engelhardt, B.; Sorokin, L. The blood-brain and the bloodcerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol., 2009, 31(4), 497-511.
58. Gao, B.; Meier, P.J. Organic anion transport across the choroid plexus. Microsc. Res. Tech., 2001, 52(1), 60-64.
59. Kusuhara, H.; Sugiyama, Y. Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv. Drug Deliv. Rev., 2004, 56(12), 1741-1763.
60. Strazielle, N.; Khuth, S.T.; Ghersi-Egea, J.F. Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv. Drug Deliv. Rev., 2004, 56(12), 1717-1740.
61. Sheiner, L.B.; Steimer, J.L. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 67-95.
62. Veszelka, S.; Kittel, A.; Deli, M.A. Solubility, Delivery ADME Probl. Drugs Drug-Candidates; Deli, Maria A., Ed.; Bentham: U.A.E, 2011, Vol 1, pp. 166-188.
63. Vastag, M.; Keseru, G.M. Current in vitro and in silico models of blood-brain barrier penetration: a practical view. Curr. Opin. Drug Discov. Devel., 2009, 12(1), 115-124.
64. Abbott, N.J. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov. Today. Technol., 2004, 1(4), 407-416.
65. Stanimirovic, D.B.; Bani-Yaghoub, M.; Perkins, M.; Haqqani, A.S. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNStargeting biotherapeutics. Expert Opin. Drug Discov., 2015, 10(2), 141-155.
66. Gumbleton, M.; Audus, K.L. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J. Pharm. Sci., 2001, 90(11), 1681-1698.
67. Reichel, A.; Begley, D.J.; Abbott, N.J. An Overview of In Vitro Techniques for Blood-brain barrier studies; In: Blood- Brain Barrier Biology and Research Protocols: Sukriti, N.; Ed.; Hunana-Press, 2003, pp. 307-324.
68. Juergenliemk, G.; Boje, K.; Huewel, S.; Lohmann, C.; Galla, H.J.; Nahrstedt, A. In vitro studies indicate that miquelianin (quercetin 3-O-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. Planta Med., 2003, 69(11), 1013-1017.
69. Yang, Z.H.; Sun, X.; Mei, C.; Sun, X.B.; Liu, X.D.; Chang, Q. An in vitro transport model for rapid screening and predicting the permeability of candidate compounds at bloodbrain barrier. J. Asian Nat. Prod. Res., 2011, 13(12), 1087-1097.
70. Faria, A.; Pestana, D.; Teixeira, D.; Couraud, P-O.; Romero, I.; Weksler, B.; de Freitas, V.; Mateus, N.; Calhau, C. Insights into the putative catechin and epicatechin transport across blood-brain barrier. Food Funct., 2011, 2(1), 39-44.
71. Wilhelm, I.; Fazakas, C.; Krizbai, I.A. In vitro models of the blood-brain barrier. Acta Neurobiol. Exp. (Warsz.), 2011, 71(1), 113-128.
72. Youdim, K.A.; Dobbie, M.S.; Kuhnle, G.; Proteggente, A.R.; Abbott, N.J.; Rice-Evans, C. Interaction between flavonoids and the blood-brain barrier: in vitro studies. J. Neurochem., 2003, 85(1), 180-192.
73. Faria, A.; Pestana, D.; Teixeira, D.; Azevedo, J.; De Freitas, V.; Mateus, N.; Calhau, C. Flavonoid transport across RBE4 cells: A blood-brain barrier model. Cell. Mol. Biol. Lett., 2010, 15(2), 234-241.
74. Youdim, K.A.; Qaiser, M.Z.; Begley, D.J.; Rice-Evans, C.A.; Abbott, N.J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med., 2004, 36(5), 592-604.
75. Ishisaka, A.; Ichikawa, S.; Sakakibara, H.; Piskula, M.K.; Nakamura, T.; Kato, Y.; Ito, M.; Miyamoto, K.; Tsuji, A.; Kawai, Y.; Terao, J. Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. Free Radic. Biol. Med., 2011, 51(7), 1329-1336.
76. Ishisaka, A.; Mukai, R.; Terao, J.; Shibata, N.; Kawai, Y. Specific localization of quercetin-3-O-glucuronide in human brain. Arch. Biochem. Biophys., 2014, 557, 11-17.
77. Faria, A.; Meireles, M.; Fernandes, I.; Santos-Buelga, C.; Gonzalez-Manzano, S.; Duenas, M.; de Freitas, V.; Mateus, N.; Calhau, C. Flavonoid metabolites transport across a human BBB model. Food Chem., 2014, 149, 190-196.
78. Ohtsuki, S.; Ikeda, C.; Uchida, Y.; Sakamoto, Y.; Miller, F.; Glacial, F.; Decleves, X.; Scherrmann, J-M.; Couraud, PO.; Kubo, Y.; Tachikawa, M.; Terasaki, T. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol. Pharm., 2013, 10(1), 289-296.
79. Yang, Y.; Bai, L.; Li, X.; Xiong, J.; Xu, P.; Guo, C.; Xue, M. Transport of active flavonoids, based on cytotoxicity and lipophilicity: an evaluation using the blood-brain barrier cell and Caco-2 cell models. Toxicol. In Vitro, 2014, 28(3), 388-396.
80. Rothwell, J.A.; Day, A.J.; Morgan, M.R. Experimental determination of octanol-water partition coefficients of quercetin and related flavonoids. J. Agric. Food Chem., 2005, 53(11), 4355-4360.
81. Karamanos, Y.; Gosselet, F.; Dehouck, M.P.; Cecchelli, R. Blood-brain barrier proteomics: towards the understanding of neurodegenerative diseases. Arch. Med. Res., 2014, 45(8), 730-737.
82. Pike, A.F.; Kramer, N.I.; Blaauboer, B.J.; Seinen, W.; Brands, R. An alkaline phosphatase transport mechanism in the pathogenesis of Alzheimer's disease and neurodegeneration. Chem. Biol. Interact., 2015, 226, 30-39.
83. Calhau, C.; Martel, F.; Hipolito-Reis, C.; Azevedo, I. Effect of P-glycoprotein modulators on alkaline phosphatase activity in cultured rat hepatocytes. Cell. Physiol. Biochem., 2000, 10(4), 195-202.
84. Moreira, P.I.; Duarte, A.I.; Santos, M.S.; Rego, A.C.; Oliveira, C.R. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J. Alzheimers Dis., 2009, 16(4), 741-761.
85. Calhau, C.; Martel, F.; Pinheiro-Silva, S.; Pinheiro, H.; Soares-da-Silva, P.; Hipolito-Reis, C.; Azevedo, I. Modulation of insulin transport in rat brain microvessel endothelial cells by an ecto-phosphatase activity. J. Cell. Biochem., 2002, 84(2), 389-400.
86. Ross, J.A.; Kasum, C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 2002, 22, 19-34.
87. Ishisaka, A.; Kawabata, K.; Miki, S.; Shiba, Y.; Minekawa, S.; Nishikawa, T.; Mukai, R.; Terao, J.; Kawai, Y. Mitochondrial dysfunction leads to deconjugation of quercetin glucuronides in inflammatory macrophages. PLoS One, 2013, 8(11), e80843.
88. De Gregori, S.; De Gregori, M.; Ranzani, G.N.; Allegri, M.; Minella, C.; Regazzi, M. Morphine metabolism, transport and brain disposition. Metab. Brain Dis., 2012, 27(1), 1-5.
89. Lu, Q.Y.; Zhang, L.; Eibl, G.; Go, V.L. Overestimation of flavonoid aglycones as a result of the ex vivo deconjugation of glucuronides by the tissue β -glucuronidase. J. Pharm. Biomed. Anal., 2014, 88, 364-369.
90. Kusch-Poddar, M.; Drewe, J.; Fux, I.; Gutmann, H. Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the bloodbrain barrier. Brain Res., 2005, 1064(1-2), 21-31.
91. Abbott, N.J.; Dolman, D.E.; Drndarski, S.; Fredriksson, S.M. An improved in vitro blood-brain barrier model: rat brain endothelial cells co-cultured with astrocytes. Methods Mol. Biol., 2012, 814, 415-430.
92. Nakagawa, S.; Deli, M.A.; Kawaguchi, H.; Shimizudani, T.; Shimono, T.; Kittel, A.; Tanaka, K.; Niwa, M. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int., 2009, 54(3-4), 253-263.
93. Hosoya, K.; Hori, S.; Ohtsuki, S.; Terasaki, T. A new in vitro model for blood-cerebrospinal fluid barrier transport studies: an immortalized choroid plexus epithelial cell line derived from the tsA58 SV40 large T-antigen gene transgenic rat. Adv. Drug Deliv. Rev., 2004, 56(12), 1875-1885.
94. Klas, J.; Wolburg, H.; Terasaki, T.; Fricker, G.; Reichel, V. Characterization of immortalized choroid plexus epithelial cell lines for studies of transport processes across the bloodcerebrospinal fluid barrier. Cerebrospinal Fluid Res., 2010, 7, 11.
95. Kitazawa, T.; Hosoya, K.; Watanabe, M.; Takashima, T.; Ohtsuki, S.; Takanaga, H.; Ueda, M.; Yanai, N.; Obinata, M.; Terasaki, T. Characterization of the amino acid trans port of new immortalized choroid plexus epithelial cell lines: a novel in vitro system for investigating transport functions at the blood-cerebrospinal fluid barrier. Pharm. Res., 2001, 18(1), 16-22.
96. Watson, R.R.; Preedy, V.R. Polyphenols in Human Health Disease, Ziberna, L.; Fornasaro, S.; Vorovic, C.J.; Tramer F.; Passamonti, S, 1st ed; Elsevier Science B. V: Amsterdam, 2014, Vol. 1, pp. 489-511.
97. Urquhart, B.L.; Kim, R.B. Blood-brain barrier transporters and response to CNS-active drugs. Eur. J. Clin. Pharmacol., 2009, 65(11), 1063-1070.
98. Stieger, B.; Gao, B. Drug transporters in the central nervous system. Clin. Pharmacokinet., 2015, 54(3), 225-242.
99. Fricker, G. Drug interactions with natural products at the blood brain barrier. Curr. Drug Metab., 2008, 9(10), 1019-1026.
100. Campos-Bedolla, P.; Walter, F.R.; Veszelka, S.; Deli, M.A. Role of the blood-brain barrier in the nutrition of the central nervous system. Arch. Med. Res., 2014, 45(8), 610-638.
101. Li, Y.; Lu, J.; Paxton, J.W. The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics. Curr. Drug Metab., 2012, 13(5), 624-639.
102. Roth, M.; Obaidat, A.; Hagenbuch, B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br. J. Pharmacol., 2012, 165(5), 1260-1287.
103. Gonzales, G.B.; Van Camp, J.; Vissenaekens, H.; Raes, K.; Smagghe, G.; Grootaert, C. Review on the use of cell cultures to study metabolism, transport, and accumulation of flavonoids: from mono-cultures to co-culture systems. Compr. Rev. Food Sci. Food Saf., 2015, 14(6), 741-754.
104. Alvarez, A.I.; Real, R.; Perez, M.; Mendoza, G.; Prieto, J.G.; Merino, G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J. Pharm. Sci., 2010, 99(2), 598-617.
105. Morris, M.E.; Zhang, S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci., 2006, 78(18), 2116-2130.
106. Miller, D.S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci., 2010, 31(6), 246-254.
107. Lo, A.; Burckart, G.J. P-glycoprotein and drug therapy in organ transplantation. J. Clin. Pharmacol., 1999, 39(10), 995-1005.
108. Mitsunaga, Y.; Takanaga, H.; Matsuo, H.; Naito, M.; Tsuruo, T.; Ohtani, H.; Sawada, Y. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur. J. Pharmacol., 2000, 395(3), 193-201.
109. Weber, C.C.; Kressmann, S.; Fricker, G.; Muller, W.E. Modulation of P-glycoprotein function by St John's wort extract and its major constituents. Pharmacopsychiatry, 2004, 37(6), 292-298.
110. Tiberghien, F.; Loor, F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs, 1996, 7(5), 568-578.
111. Gonzales, G.B.; Smagghe, G.; Grootaert, C.; Zotti, M.; Raes, K.; Van Camp, J. Flavonoid interactions during digestion, absorption, distribution and metabolism: a sequential structure-activity/property relationship-based approach in the study of bioavailability and bioactivity. Drug Metab. Rev., 2015, 47(2), 175-190.
112. Sheu, M.-T.; Liou, Y.-B.; Kao, Y.-H.; Lin, Y.-K.; Ho, H.- O. A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoproteinmediated transport. Chem. Pharm. Bull. (Tokyo), 2010, 58(9), 1187-1194.
113. Ferreira, A.; Pousinho, S.; Fortuna, A.; Falcao, A.; Alves, G. Flavonoid compounds as reversal agents of the Pglycoprotein- mediated multidrug resistance: biology, chemistry and pharmacology. Phytochem. Rev., 2015, 14(2), 233-272.
114. Doyle, L.; Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22(47), 7340-7358.
115. Jani, M.; Ambrus, C.; Magnan, R.; Jakab, K.T.; Beery, E.; Zolnerciks, J.K.; Krajcsi, P. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. Arch. Toxicol., 2014, 88(6), 1205-1248.
116. Pick, A.; Muller, H.; Mayer, R.; Haenisch, B.; Pajeva, I.K.; Weigt, M.; Bonisch, H.; Muller, C.E.; Wiese, M. Structureactivity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg. Med. Chem., 2011, 19(6), 2090-2102.
117. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 2005, 204(3), 216-237.
118. Nakatsuma, A.; Fukami, T.; Suzuki, T.; Furuishi, T.; Tomono, K.; Hidaka, S. Effects of kaempferol on the mechanisms of drug resistance in the human glioblastoma cell line T98G. Pharmazie, 2010, 65(5), 379-383.
119. van Zanden, J.J.; Wortelboer, H.M.; Bijlsma, S.; Punt, A.; Usta, M.; Bladeren, P.J.; Rietjens, I.M.; Cnubben, N.H. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol., 2005, 69(4), 699-708.
120. Mrozikiewicz, P.M.; Bogacz, A.; Bartkowiak-Wieczorek, J.; Kujawski, R.; Mikolajczak, P.L.; Ozarowski, M.; Czerny, B.; Mrozikiewicz-Rakowska, B.; Grzeskowiak, E. Screening for impact of popular herbs improving mental abilities on the transcriptional level of brain transporters. Acta Pharm., 2014, 64(2), 223-232.
121. Maestro, A.; Terdoslavich, M.; Vanzo, A.; Kuku, A.; Tramer, F.; Nicolin, V.; Micali, F.; Decorti, G.; Passamonti, S. Expression of bilitranslocase in the vascular endothelium and its function as a flavonoid transporter. Cardiovasc. Res., 2010, 85(1), 175-183.
122. Passamonti, S.; Vrhovsek, U.; Mattivi, F. The interaction of anthocyanins with bilitranslocase. Biochem. Biophys. Res. Commun., 2002, 296(3), 631-636.
123. Lee, J.H.; Lee, J.E.; Kim, Y.; Lee, H.; Jun, H.J.; Lee, S-J. Multidrug and toxic compound extrusion protein-1 (MATE1/SLC47A1) is a novel flavonoid transporter. J. Agric. Food Chem., 2014, 62(40), 9690-9698.
124. Vaidyanathan, J.B.; Walle, T. Cellular uptake and efflux of the tea flavonoid (-)epicatechin-3-gallate in the human intestinal cell line Caco-2. J. Pharmacol. Exp. Ther., 2003, 307(2), 745-752.
125. Konishi, Y. Transepithelial transport of microbial metabolites of quercetin in intestinal Caco-2 cell monolayers. J. Agric. Food Chem., 2005, 53(3), 601-607.
126. Konishi, Y.; Kobayashi, S.; Shimizu, M. Tea polyphenols inhibit the transport of dietary phenolic acids mediated by the monocarboxylic acid transporter (MCT) in intestinal Caco-2 cell monolayers. J. Agric. Food Chem., 2003, 51(25), 7296-7302.
127. Kobayashi, S.; Konishi, Y. Transepithelial transport of flavanone in intestinal Caco-2 cell monolayers. Biochem. Biophys. Res. Commun., 2008, 368(1), 23-29.
128. Wu, C.P.; Calcagno, A.M.; Hladky, S.B.; Ambudkar, S.V.; Barrand, M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J., 2005, 272(18), 4725-4740.
129. Wang, X.; Wolkoff, A.W.; Morris, M.E. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab. Dispos., 2005, 33(11), 1666-1672.
130. Zhang, Y.; Hays, A.; Noblett, A.; Thapa, M.; Hua, D.H.; Hagenbuch, B. Transport by OATP1B1 and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several quercetin derivatives. J. Nat. Prod., 2013, 76(3), 368-373.
131. Patching, S.G. Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol. Neurobiol., 2016, 1-32. [Epub ahead of print].
132. Hong, S.S.; Seo, K.; Lim, S.C.; Han, H.K. Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3). Pharmacol. Res., 2007, 56(6), 468-473.
133. Wong, C.C.; Botting, N.P.; Orfila, C.; Al-Maharik, N.; Williamson, G. Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6). Biochem. Pharmacol., 2011, 81(7), 942-949.
134. de Lange, E.C. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev., 2004, 56(12), 1793-1809.
135. Nam, Y.; Choi, M.; Hwang, H.; Lee, M.G.; Kwon, B.M.; Lee, W.H.; Suk, K. Natural flavone jaceosidin is a neuroinflammation inhibitor. Phytother. Res., 2013, 27(3), 404-411.
136. Wang, J.; Ferruzzi, M.G.; Ho, L.; Blount, J.; Janle, E.M.; Gong, B.; Pan, Y.; Gowda, G.A.; Raftery, D.; Arrieta-Cruz, I.; Sharma, V.; Cooper, B.; Lobo, J.; Simon, J.E.; Zhang, C.; Cheng, A.; Qian, X.; Ono, K.; Teplow, D.B.; Pavlides, C.; Dixon, R.A.; Pasinetti, G.M. Brain-targeted proanthocyanidin metabolites for Alzheimer's disease treatment. J. Neurosci., 2012, 32(15), 5144-5150.
137. Hou, Y.; Aboukhatwa, M.A.; Lei, D.L.; Manaye, K.; Khan, I.; Luo, Y. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology, 2010, 58(6), 911-920.
138. Arsalandeh, F.; Ahmadian, S.; Foolad, F.; Khodagholi, F.; Farimani, M.M.; Shaerzadeh, F. Beneficial effect of flavone derivatives on abeta-induced memory deficit is mediated by peroxisome proliferator-activated receptor coactivator 1alpha: a comparative study. Int. J. Toxicol., 2015, 34(3), 274-283.
139. Ho, L.; Ferruzzi, M.G.; Janle, E.M.; Wang, J.; Gong, B.; Chen, T.Y.; Lobo, J.; Cooper, B.; Wu, Q.L.; Talcott, S.T.; Percival, S.S.; Simon, J.E.; Pasinetti, G.M. Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease. FASEB J., 2013, 27(2), 769-781.
140. Liu, R.; Wu, C.-X.; Zhou, D.; Yang, F.; Tian, S.; Zhang, L.; Zhang, T.-T.; Du, G.-H. Pinocembrin protects against β - amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)- independent signaling pathways and regulating mitochondrion- mediated apoptosis. BMC Med., 2012, 10, 105.
141. Yoshino, S.; Hara, A.; Sakakibara, H.; Kawabata, K.; Tokumura, A.; Ishisaka, A.; Kawai, Y.; Terao, J. Effect of quercetin and glucuronide metabolites on the monoamine oxidase-A reaction in mouse brain mitochondria. Nutrition, 2011, 27(7-8), 847-852.
142. Andres-Lacueva, C.; Shukitt-Hale, B.; Galli, R.L.; Jauregui, O.; Lamuela-Raventos, R.M.; Joseph, J.A. Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. Nutr. Neurosci., 2005, 8(2), 111-120.
143. Xu, B.; Li, X.X.; He, G.R.; Hu, J.J.; Mu, X.; Tian, S.; Du, G.H. Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats. Eur. J. Pharmacol., 2010, 627(1-3), 99-105.
144. Liu, R.; Gao, M.; Qiang, G.F.; Zhang, T.T.; Lan, X.; Ying, J.; Du, G.H. The anti-amnesic effects of luteolin against amyloid beta(25-35) peptide-induced toxicity in mice involve the protection of neurovascular unit. Neuroscience, 2009, 162(4), 1232-1243.
145. Priprem, A.; Watanatorn, J.; Sutthiparinyanont, S.; Phachonpai, W.; Muchimapura, S. Anxiety and cognitive effects of quercetin liposomes in rats. Nanomedicine (Lond.), 2008, 4(1), 70-78.
146. Kavvadias, D.; Sand, P.; Youdim, K.A.; Qaiser, M.Z.; Rice- Evans, C.; Baur, R.; Sigel, E.; Rausch, W.D.; Riederer, P.; Schreier, P. The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. Br. J. Pharmacol., 2004, 142(5), 811-820.
147. Lou, H.; Jing, X.; Wei, X.; Shi, H.; Ren, D.; Zhang, X. Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway. Neuropharmacology, 2014, 79, 380-388.
148. Roghani, M.; Niknam, A.; Jalali-Nadoushan, M.R.; Kiasalari, Z.; Khalili, M.; Baluchnejadmojarad, T. Oral pelargonidin exerts dose-dependent neuroprotection in 6- hydroxydopamine rat model of hemi-parkinsonism. Brain Res. Bull., 2010, 82(5-6), 279-283.
149. Takumi, H.; Mukai, R.; Ishiduka, S.; Kometani, T.; Terao, J. Tissue distribution of hesperetin in rats after a dietary intake. Biosci. Biotechnol. Biochem., 2011, 75(8), 1608-1610.
150. Datla, K.P.; Christidou, M.; Widmer, W.W.; Rooprai, H.K.; Dexter, D.T. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport, 2001, 12(17), 3871-3875.
151. Saigusa, D.; Shibuya, M.; Jinno, D.; Yamakoshi, H.; Iwabuchi, Y.; Yokosuka, A.; Mimaki, Y.; Naganuma, A.; Ohizumi, Y.; Tomioka, Y.; Yamakuni, T. High-performance liquid chromatography with photodiode array detection for determination of nobiletin content in the brain and serum of mice administrated the natural compound. Anal. Bioanal. Chem., 2011, 400(10), 3635-3641.
152. Peng, H.W.; Cheng, F.C.; Huang, Y.T.; Chen, C.F.; Tsai, T.H. Determination of naringenin and its glucuronide conjugate in rat plasma and brain tissue by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl., 1998, 714(2), 369-374.
153. Krasieva, T.B.; Ehren, J.; O'Sullivan, T.; Tromberg, B.J.; Maher, P. Cell and brain tissue imaging of the flavonoid fisetin using label-free two-photon microscopy. Neurochem. Int., 2015, 89, 243-248.
154. de Boer, V. C. J.; Dihal, A. de Boer, V.C.; Dihal, A.A.; van der Woude, H.; Arts, I.C.; Wolffram, S.; Alink, G.M.; Rietjens, I.M.; Keijer, J.; Hollman, P.C. Tissue distribution of quercetin in rats and pigs. J. Nutr., 2005, 135(7), 1718-1725.
155. Paulke, A.; Eckert, G.P.; Schubert-Zsilavecz, M.; Wurglics, M. Isoquercitrin provides better bioavailability than quercetin: comparison of quercetin metabolites in body tissue and brain sections after six days administration of isoquercitrin and quercetin. Pharmazie, 2012, 67(12), 991-996.
156. Paulke, A.; Schubert-Zsilavecz, M.; Wurglics, M. Determination of St. John's wort flavonoid-metabolites in rat brain through high performance liquid chromatography coupled with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2006, 832(1), 109-113.
157. Bieger, J.; Cermak, R.; Blank, R.; de Boer, V.C.; Hollman, P.C.; Kamphues, J.; Wolffram, S. Tissue distribution of quercetin in pigs after long-term dietary supplementation. J. Nutr., 2008, 138(8), 1417-1420.
158. Wiczkowski, W.; Skipor, J.; Misztal, T.; Szawara-Nowak, D.; Topolska, J.; Piskula, M.K. Quercetin and isorhamnetin aglycones are the main metabolites of dietary quercetin in cerebrospinal fluid. Mol. Nutr. Food Res., 2015, 59(6), 1088-1094.
159. Abd El Mohsen, M.M.; Kuhnle, G.; Rechner, A.R.; Schroeter, H.; Rose, S.; Jenner, P.; Rice-Evans, C.A. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic. Biol. Med., 2002, 33(12), 1693-1702.
160. Ouzzine, M.; Gulberti, S.; Ramalanjaona, N.; Magdalou, J.; Fournel-Gigleux, S. The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication. Front. Cell. Neurosci., 2014, 8, 349.
161. O'Leary, K.A.; Day, A.J.; Needs, P.W.; Sly, W.S.; O'Brien, N.M.; Williamson, G. Flavonoid glucuronides are substrates for human liver beta-glucuronidase. FEBS Lett., 2001, 503(1), 103-106.
162. Zini, A.; Del Rio, D.; Stewart, A.J.; Mandrioli, J.; Merelli, E.; Sola, P.; Nichelli, P.; Serafini, M.; Brighenti, F.; Edwards, C.A.; Crozier, A. Do flavan-3-ols from green tea reach the human brain? Nutr. Neurosci., 2006, 9(1-2), 57-61.
163. Prior, R.L.; Wu, X. Anthocyanins: structural characteristics that result in unique metabolic patterns and biological activities. Free Radic. Res., 2006, 40(10), 1014-1028.
164. Borges, G.; Roowi, S.; Rouanet, J.M.; Duthie, G.G.; Lean, M.E.; Crozier, A. The bioavailability of raspberry anthocyanins and ellagitannins in rats. Mol. Nutr. Food Res., 2007, 51(6), 714-725.
165. El Mohsen, M.A.; Marks, J.; Kuhnle, G.; Moore, K.; Debnam, E.; Kaila Srai, S.; Rice-Evans, C.; Spencer, J.P. Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats. Br. J. Nutr., 2006, 95(1), 51-58.
166. Talavera, S.; Felgines, C.; Texier, O.; Besson, C.; Gil- Izquierdo, A.; Lamaison, J.L.; Remesy, C. Anthocyanin metabolism in rats and their distribution to digestive area, kidney, and brain. J. Agric. Food Chem., 2005, 53(10), 3902-3908.
167. Passamonti, S.; Vrhovsek, U.; Vanzo, A.; Mattivi, F. Fast access of some grape pigments to the brain. J. Agric. Food Chem., 2005, 53(18), 7029-7034.
168. Kalt, W.; Blumberg, J.B.; McDonald, J.E.; Vinqvist- Tymchuk, M.R.; Fillmore, S.A.; Graf, B.A.; O'Leary, J.M.; Milbury, P.E. Identification of anthocyanins in the liver, eye, and brain of blueberry-fed pigs. J. Agric. Food Chem., 2008, 56(3), 705-712.
169. Milbury, P.E.; Kalt, W. Xenobiotic metabolism and berry flavonoid transport across the blood-brain barrier. J. Agric. Food Chem., 2010, 58(7), 3950-3956.
170. Lewandowska, U.; Szewczyk, K.; Hrabec, E.; Janecka, A.; Gorlach, S. Overview of metabolism and bioavailability enhancement of polyphenols. J. Agric. Food Chem., 2013, 61(50), 12183-12199.
171. Bilia, A.R.; Isacchi, B.; Righeschi, C.; Guccione, C.; Bergonzi, M.C. Flavonoids loaded in nanocarriers: an opportunity to increase oral bioavailability and bioefficacy. Food Nutr. Sci., 2014, 5(5), 1212-1227.
172. Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release, 2012, 161(2), 264-273.
173. Patel, T.; Zhou, J.; Piepmeier, J.M.; Saltzman, W.M. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev., 2012, 64(7), 701-705.
174. Kreuter, J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv. Drug Deliv. Rev., 2014, 71(1), 2-14.
175. Wagner, S.; Zensi, A.; Wien, S.L.; Tschickardt, S.E.; Maier, W.; Vogel, T.; Worek, F.; Pietrzik, C.U.; Kreuter, J.; von Briesen, H. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One, 2012, 7(3), e32568.
176. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm., 2009, 71(2), 251-256.
177. Testa, G.; Gamba, P.; Badilli, U.; Gargiulo, S.; Maina, M.; Guina, T.; Calfapietra, S.; Biasi, F.; Cavalli, R.; Poli, G.; Leonarduzzi, G. Loading into nanoparticles improves quercetin's efficacy in preventing neuroinflammation induced by oxysterols. PLoS One, 2014, 9(5), e96795.
178. Ghosh, A.; Sarkar, S.; Mandal, A.K.; Das, N. Neuroprotective role of nanoencapsulated quercetin in combating ischemia-reperfusion induced neuronal damage in young and aged rats. PLoS One, 2013, 8(4), e57735.
179. Das, S.; Mandal, A.K.; Ghosh, A.; Panda, S.; Das, N.; Sarkar, S. Nanoparticulated quercetin in combating age related cerebral oxidative injury. Curr. Aging Sci., 2008, 1(3), 169-174.
180. Ghosh, A.; Mandal, A.K.; Sarkar, S.; Panda, S.; Das, N. Nanoencapsulation of quercetin enhances its dietary efficacy in combating arsenic-induced oxidative damage in liver and brain of rats. Life Sci., 2009, 84(3-4), 75-80.
181. Ghosh, S.; Dungdung, S.R.; Chowdhury, S.T.; Mandal, A.K.; Sarkar, S.; Ghosh, D.; Das, N. Encapsulation of the flavonoid quercetin with an arsenic chelator into nanocapsules enables the simultaneous delivery of hydrophobic and hydrophilic drugs with a synergistic effect against chronic arsenic accumulation and oxidative stress. Free Radic. Biol. Med., 2011, 51(10), 1893-1902.
182. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47(1), 65-81.
183. Bagad, M.; Khan, Z.A. Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats. Int. J. Nanomedicine, 2015, 10, 3921-3935.
184. Nday, C.M.; Halevas, E.; Jackson, G.E.; Salifoglou, A. Quercetin encapsulation in modified silica nanoparticles: potential use against Cu(II)-induced oxidative stress in neurodegeneration. J. Inorg. Biochem., 2015, 145, 51-64.
185. Diniz, A.; Escuder-Gilabert, L.; Lopes, N.P.; Gobbo-Neto, L.; Villanueva-Camanas, R.M.; Sagrado, S.; Medina- Hernandez, M.J. Permeability profile estimation of flavonoids and other phenolic compounds by biopartitioning micellar capillary chromatography. J. Agric. Food Chem., 2007, 55(21), 8372-8379.
186. De Vrieze, M.; Lynen, F.; Chen, K.; Szucs, R.; Sandra, P. Predicting drug penetration across the blood-brain barrier: comparison of micellar liquid chromatography and immobilized artificial membrane liquid chromatography. Anal. Bioanal. Chem., 2013, 405(18), 6029-6041.
187. Blasi, P.; Giovagnoli, S.; Schoubben, A.; Ricci, M.; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev., 2007, 59(6), 454-477.
188. Dhawan, S.; Kapil, R.; Singh, B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J. Pharm. Pharmacol., 2011, 63(3), 342-351.
189. Fang, C-L.; Al-Suwayeh, S.A.; Fang, J.Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat. Nanotechnol., 2013, 7(1), 41-55.
190. Tsai, M.J.; Wu, P.C.; Huang, Y.B.; Chang, J.S.; Lin, C.L.; Tsai, Y.H.; Fang, J.Y. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int. J. Pharm., 2012, 423(2), 461-470.
191. Shinde, R.L.; Jindal, A.B.; Devarajan, P.V. Microemulsions and nanoemulsions for targeted drug delivery to the brain. Curr. Nanosci., 2011, 7(1), 119-133.
192. Yao, J.; Zhou, J.P.; Ping, Q.N.; Lu, Y.; Chen, L. Distribution of nobiletin chitosan-based microemulsions in brain following i.v. injection in mice. Int. J. Pharm., 2008, 352(1- 2), 256-262.
193. Lai, F.; Fadda, A.M.; Sinico, C. Liposomes for brain delivery. Expert Opin. Drug Deliv., 2013, 10(7), 1003-1022.
194. Huang, Y.-B.; Tsai, M.-J.; Wu, P.-C.; Tsai, Y.-H.; Wu, Y.- H.; Fang, J.-Y. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. J. Drug Target., 2011, 19(8), 709-718.
195. Liew, K.F.; Chan, K.L.; Lee, C.Y. Blood-brain barrier permeable anticholinesterase aurones: synthesis, structureactivity relationship, and drug-like properties. Eur. J. Med. Chem., 2015, 94, 195-210.
196. Scheepens, A.; Tan, K.; Paxton, J.W. Improving the oral bioavailability of beneficial polyphenols through designed synergies. Genes Nutr., 2010, 5(1), 75-87.
197. Ferri, P.; Angelino, D.; Gennari, L.; Benedetti, S.; Ambrogini, P.; Del Grande, P.; Ninfali, P. Enhancement of flavonoid ability to cross the blood-brain barrier of rats by coadministration with alpha-tocopherol. Food Funct. 2015, 6(2), 394-400.